Glaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +110.7%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
Follow GKOS
Alert me
Glaukos Corporation (GKOS) P/B ratio
As of 5 November 2026, Glaukos Corporation (GKOS) trades at a P/B ratio of 18.1×. Over the past ten years it has ranged from 0.0× (June 2015) to 20.3× (November 2026); the current reading is higher than 100% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 9.8× | (4.58%) |
| FY2024 | 10.3× | 27.57% |
| FY2023 | 8.1× | 105.82% |
| FY2022 | 3.9× | 11.79% |
| FY2021 | 3.5× | (29.97%) |
| FY2020 | 5.0× | 66.02% |
| FY2019 | 3.0× | (73.51%) |
| FY2018 | 11.4× | 69.37% |
| FY2017 | 6.7× | (28.85%) |
| FY2016 | 9.5× | 108.90% |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 13.5× | 12.33% |
| Jun 2026 | 12.0× | 29.37% |
| Mar 2026 | 9.3× | (5.39%) |
| Dec 2025 | 9.8× | 61.79% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| BIO Bio-Rad Laboratories, Inc. compare | 1.3× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 1.3× |
| ZBH Zimmer Biomet Holdings, Inc. compare | 1.6× |
| GMED Globus Medical, Inc. compare | 2.3× |
| SNN Smith & Nephew SNATS, Inc. compare | 2.8× |
| BRKR Bruker Corporation compare | 3.7× |
| PODD Insulet Corporation compare | 7.6× |
| PEN Penumbra, Inc. compare | 8.0× |
| GKOS Glaukos Corporation | 18.1× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on GKOS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement